Five decades of therapy for multiple myeloma: A paradigm for therapeutic models

Leukemia

Volumn 19, Issue 6, 2005, Pages 910-912

  Kyle, Robert A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; CALCIUM; CARMUSTINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; M PROTEIN; MELPHALAN; PLACEBO; PREDNISONE; STILBAMIDINE; THALIDOMIDE; URETHAN;

ACUTE LEUKEMIA; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW EXAMINATION; CANCER RESEARCH; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELODYSPLASIA; NAUSEA AND VOMITING; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OSTEOLYSIS; PATIENT CARE; PERIPHERAL NEUROPATHY; PHYSICIAN ATTITUDE; PLASMA CELL; PRIORITY JOURNAL; RISK ASSESSMENT; SENSORIMOTOR NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; HISTORY; ONCOLOGY;

HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MEDICAL ONCOLOGY; MULTIPLE MYELOMA;

EID: 20844448915     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403728     Document Type: Article

References (22)

1. Kyle RA. Multiple myeloma: how did it begin? Mayo Clin Proc 1994; 69: 680-683.
2. Paul JR. Stanhope Bayne-Jones (1888-1970). Medical dean, military hero, microbiologist and epidemiologist, and medical historian. Yale J Biol Med 1972; 45: 22-32.
3. Korngold L, Lipari R. Multiple-myeloma proteins. III. The antigenic relationship of Bence Jones proteins to normal gammaglobulin and multiple-myeloma serum proteins. Cancer 1956; 9: 262-272.
4. Korngold L, Lipari R. Multiple-myeloma proteins. I. Immunological studies. Cancer 1956; 9: 183-192.
5. Edelman GM, Gally JA. The nature of Bence Jones proteins. Chemical similarities to polypetide chains of myeloma globulins and normal gamma-globulins. J Exp Med 1962; 116: 207-227.
6. Alwall N. Urethane and stilbamidine in multiple myeloma: Report on two cases. Lancet 1947; 2: 388-389.
7. Alwall N. Urethane in multiple myeloma. I. Final report of a case treated more than four years with urethane. Acta Med Scand 1952; 144: 114-118.
8. Holland JR, Hosley H, Scharlau C, Carbone PP, Frei E III, Brindley CO et al. A controlled trial of urethane treatment in multiple myeloma. Blood 1966; 27: 328-342.
9. Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N. Clinical experiences with sarcolysin in neoplastic diseases. Ann NY Acad Sci 1958; 68: 1128-1132.
10. Bergsagel DE. Phase II trials of mitomycin C, AB-100, NSC-1026, L-sarcolysin, and meta-sarcolysin, in the treatment of multiple myeloma. Cancer Chemother Rep 1962; 16: 261-266.
11. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med 1970; 283: 1121-1125.
12. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
13. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single vs double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
14. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295-1303.
15. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
16. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
17. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
18. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768-771.
19. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399-403.
20. Coleman M, Leonard J, Lyons L, Pekle K, Nahum K, Pearse R et al. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. Leuk Lymphoma 2002; 43: 1777-1782.
21. Richardson PC, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
22. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.